Last Updated : May 2, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
|---|---|---|---|---|---|---|
| Baqsimi | glucagon | Severe hypoglycemic reactions | Reimburse with clinical criteria and/or conditions | Complete | ||
| Tecentriq | Atezolizumab | Small Cell Lung Cancer (SCLC) | Do not reimburse | Complete | ||
| Lorbrena | Lorlatinib | Non-Small Cell Lung Cancer (NSCLC) | Do not reimburse | Complete | ||
| Rinvoq | upadacitinib | Arthritis, Rheumatoid | Reimburse with clinical criteria and/or conditions | Complete | ||
| Trintellix | vortioxetine hydrobromide | Major depressive disorder (MDD), adults. | Reimburse with clinical criteria and/or conditions | Complete | ||
| Vyndaqel | tafamidis | transthyretin-mediated amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Darzalex | Daratumumab | Rd for MM | Reimburse with clinical criteria and/or conditions | Complete | ||
| Taltz | ixekizumab | Ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lonsurf | Trifluridine-Tipiracil | Gastric Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Monoferric | Iron (III) Isomaltoside 1000 | iron deficiency anemia | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 2, 2024